TY - JOUR
T1 - Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia
T2 - a therapeutic advances in childhood leukemia & lymphoma study
AU - Sun, Weili
AU - Malvar, Jemily
AU - Sposto, Richard
AU - Verma, Anupam
AU - Wilkes, Jennifer J.
AU - Dennis, Robyn
AU - Heym, Kenneth
AU - Laetsch, Theodore W.
AU - Widener, Melissa
AU - Rheingold, Susan R.
AU - Oesterheld, Javier
AU - Hijiya, Nobuko
AU - Sulis, Maria Luisa
AU - Huynh, Van
AU - Place, Andrew E.
AU - Bittencourt, Henrique
AU - Hutchinson, Raymond
AU - Messinger, Yoav
AU - Chang, Bill
AU - Matloub, Yousif
AU - Ziegler, David S.
AU - Gardner, Rebecca
AU - Cooper, Todd
AU - Ceppi, Francesco
AU - Hermiston, Michelle
AU - Dalla-Pozza, Luciano
AU - Schultz, Kirk R.
AU - Gaynon, Paul
AU - Wayne, Alan S.
AU - Whitlock, James A.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/11/1
Y1 - 2018/11/1
N2 - The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.
AB - The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.
UR - http://www.scopus.com/inward/record.url?scp=85046482660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046482660&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0094-0
DO - 10.1038/s41375-018-0094-0
M3 - Article
C2 - 29728694
AN - SCOPUS:85046482660
SN - 0887-6924
VL - 32
SP - 2316
EP - 2325
JO - Leukemia
JF - Leukemia
IS - 11
ER -
